Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M485Revenue $M44.4Net Margin (%)8.1Altman Z-Score4.9
Enterprise Value $M377EPS $0.1Operating Margin %5.7Piotroski F-Score7
P/E(ttm)465Beneish M-Score0.6Pre-tax Margin (%)5.8Higher ROA y-yY
Price/Book4.210-y EBITDA Growth Rate %--Quick Ratio20.6Cash flow > EarningsY
Price/Sales11.35-y EBITDA Growth Rate %--Current Ratio20.6Lower Leverage y-yY
Price/Free Cash Flow46.5y-y EBITDA Growth Rate %--ROA % (ttm)2.3Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)3.0Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M69.6ROIC % (ttm)19.5Gross Margin Increase y-yY

Gurus Latest Trades with PGNX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PGNXJulian Robertson 2014-09-30 Buy 1.8%$4.15 - $5.56
($4.99)
$ 6.9740%New holding1,290,055
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PGNX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


PGNX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ISRAEL ROBERT JExecutive Vice President, Medi 2015-06-11Sell2,000$6.832.05view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-03-13Sell3,000$7-0.43view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-03-11Sell2,000$6.832.05view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-03-03Sell5,000$6.497.4view
ISRAEL ROBERT JExecutive Vice President, Medi 2015-01-12Sell2,000$7.06-1.27view
ISRAEL ROBERT JExecutive Vice President, Medi 2014-12-11Sell3,000$7.07-1.41view
ISRAEL ROBERT JExecutive Vice President, Medi 2014-11-21Sell9,000$7-0.43view
ISRAEL ROBERT JExecutive Vice President, Medi 2014-11-13Sell10,000$6.832.05view
ISRAEL ROBERT JExecutive Vice President, Medi 2014-11-11Sell5,000$6.536.74view
Broadfin Healthcare Master Fun10% Owner 2014-07-21Buy1,625,436$4.651.52view

Quarterly/Annual Reports about PGNX:

News about PGNX:

Articles On GuruFocus.com
Tiger Management’s Julian Robertson Buys Alibaba, eBay, MasTec, Sells Tableau Software, Monsanto, Nov 14 2014 
Ex-Boxer Paul Tudor Jones Delivering Knockout Punches on Wall Street Nov 07 2014 
Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX Jan 26 2013 
Weekly CEO Buys Highlight: CVRR, HBAN, VVTV, SXCP, PGNX Jan 27 2013 
Weekly CEO Buys Highlight: SUSP, ROVI, ZLC, MDW, PGNX Oct 01 2012 
5 Stocks That Dropped the Most Since Gurus Bought Them Sep 13 2012 
Dendreon Could Push Higher If New Drug Trials Succeed Apr 23 2012 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Dec 01 2010 
Progenics Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
Progenics Pharmaceuticals Inc. (PGNX) CEO Paul J Maddon buys 5,000 Shares Nov 02 2010 

More From Other Websites
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Jul 02 2015
Needham Is Bullish On Progenics Pharmaceuticals Jun 25 2015
Valeant-Progenics Report NDA Filing for Oral Relistor in US - Analyst Blog Jun 24 2015
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 24 2015
Progenics Pharmaceuticals to Present at Cantor Fitzgerald's Inaugural Healthcare Conference Jun 24 2015
Progenics Pharmaceuticals to Present at Cantor Fitzgerald's Inaugural Healthcare Conference Jun 24 2015
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 23 2015
Valeant and Progenics Announce the Submission of U.S. New Drug Application for Oral RELISTOR® Jun 23 2015
Valeant and Progenics Announce the Submission of U.S. New Drug Application for Oral RELISTOR® Jun 23 2015
Valeant and Progenics Announce the Submission of U.S. New Drug Application for Oral RELISTOR® Jun 23 2015
Valeant and Progenics Announce the Submission of U.S. New Drug Application for Oral RELISTOR® Jun 23 2015
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security... Jun 11 2015
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 03 2015
RELISTOR(R) Receives European Approval for Expanded Indication to Treat All Opioid-Induced... Jun 03 2015
RELISTOR(R) Receives European Approval for Expanded Indication to Treat All Opioid-Induced... Jun 03 2015
PROGENICS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 28 2015
Progenics Pharmaceuticals to Present at Jefferies 2015 Healthcare Conference May 27 2015
Progenics Pharmaceuticals to Present at Jefferies 2015 Healthcare Conference May 27 2015
PROGENICS PHARMACEUTICALS INC Financials May 13 2015
10-Q for Progenics Pharmaceuticals, Inc. May 08 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK